Full-Time
Confirmed live in the last 24 hours
Develops treatments for neurological disorders
$101.2k - $146.6k/yr
Senior
Company Does Not Provide H1B Sponsorship
San Diego, CA, USA
Neurocrine Biosciences focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company has a range of FDA-approved medications for conditions such as tardive dyskinesia, Huntington's disease-related chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids. Their products work by targeting specific pathways in the brain and body to alleviate symptoms associated with these disorders. Unlike many competitors, Neurocrine emphasizes a deep understanding of the connections between brain and body systems, which informs their research and development efforts. The company's goal is to relieve suffering for patients with unmet medical needs by providing effective treatments for complex conditions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1992
Help us improve and share your feedback! Did you find this helpful?
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Parental Leave
Health Insurance
Dental Insurance
Vision Insurance
Paid Holidays
90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid Reduction. Observed Rates of Select Reproductive Hormone Normalization in Adult Males Taking CRENESSITY with Substantial Glucocorticoid Dose Reductions. Findings Presented at the 2025 American Association of Clinical Endocrinology Annual MeetingSAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont). The data showed that a substantial proportion of pediatric patients with classic congenital adrenal hyperplasia achieved physiologic-range glucocorticoid doses and normal androstenedione levels. Additionally, adult male patients with classic congenital adrenal hyperplasia observed improvements in select reproductive hormone levels. Both adult and pediatric patients achieved substantial reductions in glucocorticoid doses. These results were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando
Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical OutcomesFindings Presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual MeetingSAN DIEGO, May 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented today a systematic literature review illustrating the relationship between higher glucocorticoid dose and adverse clinical outcomes, including decreased bone mineral density, increased insulin resistance and higher body mass index, in patients with congenital adrenal hyperplasia. This study was presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in Montreal, Canada.Congenital adrenal hyperplasia (CAH) is a rare, lifelong genetic condition linked to overproduction of adrenal androgens and cortisol deficiency. CAH is traditionally treated with lifelong high-dose glucocorticoids (GCs), which increase the risk of complications across multiple aspects of health. However, the relationship between GC dose and adverse clinical outcomes in CAH has not been fully explored. This systematic literature review was conducted to analyze the relationship between GC dose and clinical outcomes, and is the first to capture the impact of higher GC dose on the incidence and severity of all relevant adverse clinical outcomes in patients with CAH."CAH requires lifelong glucocorticoid therapy to manage adrenal androgen excess and cortisol deficiency, but high doses often lead to significant complications, including cardiometabolic, bone and growth issues," said Eiry W
Nxera Pharma's partner, Neurocrine Biosciences, has launched a Phase 3 trial for NBI-1117568, an oral M4 selective receptor agonist, for schizophrenia treatment.
Neurocrine Biosciences Inc. has appointed Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025.
SAN DIEGO, March 11, 2025 /PRNewswire/ - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025.